Who is left in R&D leadership?

Discussion in 'Allergan' started by Anonymous, Jan 28, 2015 at 8:21 PM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    "Span of control" "9-box grid" - your're going to end up at 25 Technology Drive West, Suite 200. So sad, so bad, you're been had...
     

  2. anonymous

    anonymous Guest

    Is it standard practice to have a director with no real experience in his field??

    You know...the kind who sends the lowest level employee in his group to face an FDA audit.
     
  3. anonymous

    anonymous Guest

    I think you have to look at who hired them, probably will explain a lot
     
  4. anonymous

    anonymous Guest

    And it all comes back to Doc...
     
  5. anonymous

    anonymous Guest

    This is so funny. These 2 guys keep coming up on this thread. What ever happened to Aunt Bee?
     
  6. anonymous

    anonymous Guest

    I don't know...the last I saw of her was a "for sale" sign for a used mattress up on a cork board in one of the towers
     
  7. anonymous

    anonymous Guest

    This post is directed at those left in Irvine who think that facility is untouchable due to Botox. Don't be surprised if Irvine is closed soon. There's pressure to eliminate costs and Irvine is an easy target! Yes it is for all you "Botox can't be relocated over night fanatics." Repurposing of AGN legacy drugs can be done anywhere and running such a big campus has to be considered a huge detriment for the bottom line!
     
  8. anonymous

    anonymous Guest

    Not a "fanatic"...just someone who has worked in the select agent program and knows how much time and effort things like this take.

    The long term viability of the Irvine campus...who knows...it could be parsed out and sold off keeping only a small SA footprint. But to relocate SA R&D would be a multi year endeavor...this is FACT.

    It is obvious from your post that you have no clue what you are talking about should be ignored.
     
  9. anonymous

    anonymous Guest

    Irvine also seems to be hiring back a lot of scientists over 100 positions open in Irvine and new ones added each day. Not a sign of a down turn to me
     
  10. anonymous

    anonymous Guest

    agreed...we're back in building mode for our bold future.
     
  11. anonymous

    anonymous Guest

    Things are great ! We're getting the same training as the executives running Pharm Dev
    https://youtu.be/UgqGSObdyKQ
     
  12. anonymous

    anonymous Guest

    Ha, ha, ha...this is the same segment that blows their noses in the sink - disgusting people.
     
  13. anonymous

    anonymous Guest

    Is our R&D Leadership safe tomorrow?
     
  14. anonymous

    anonymous Guest

    Of course they are...nobody is ever held responsible for anything that happens below them. They fuck up and are then either promoted or moved to a different department with more responsibility. Peter Principle in action...now that's BOLD!

    And we all wonder why this once decent company (AGN) is a fucking shell of itself with no clear direction and a incompetent clown for a CEO. You know your ideas have no merit when you feel the need to propagandize to your employees on a daily basis with your stupdid PR buzzwords. Seriously...does this guy need to hire a consultant firm to take a shit?

    Gotta keep those aquisitions (or cost reductions) flowing every quarter so the street can't tell what's really going on with the books. Keep everything clear as mud and then repeat over and over how well we are doing. Fucking joke...and don't get me started on the non-GAAP.
     
  15. anonymous

    anonymous Guest



    The entire Irvine operation is now a joke. Needs to be eliminated. Everyone knows the new Allergan doesn't do R&D! Fire them all!
     
  16. anonymous

    anonymous Guest

    Doesn't do development huh? Except most of the M&A has been with clinical stage projects so you need the "D" to bring those to approval, but yeah no need for R&D (SMH)
     
  17. anonymous

    anonymous Guest

    Why do you keep coming back with your pathological resentment for these folks. R&D has had its changes, but that's life in pharma. If you're not bold enough to hang, piss off!
     
  18. anonymous

    anonymous Guest

    Cheaters gotta cheat
     
  19. anonymous

    anonymous Guest

    Texas district court ruled Restasis patents are obvious - guess who is on that patent?
     
  20. anonymous

    anonymous Guest

    What Allergan did in 2014 in regards to Restasis patents is nothing short of genius. Restasis was due to come off patent in 2014. Generic companies were already filing for approval of their drugs at that time.

    Based upon additional research that has been performed on Restasis and similar products, they filed and obtained approval for 6 additional patents. These patents extended patent protection for Restasis until 2024. It is these patents that the federal court ruled as invalid.

    If Allergan lost the patents and a generic Restasis were marketed today, Allergan already extended the exclusivity from 2014 until 2017 (most likely at least 2018). Losing the patents now is definitely a huge loss but an additional 3-4 years of patent exclusivity for a billion dollar drug is a huge win.

    Hopefully the science that allowed them to file the additional patents in 2014 is strong enough to keep the patents on appeal. If not, I am sure that there will be more challenges to obtaining approval for a generic Restasis. Restasis is a very unique formulation. Proving equivalency is very difficult.